Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Royalty Pharma comes to Adstiladrin’s rescue
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
